Mink Therapeutics: H.C. Wainwright assumes coverage with buy rating, $38 target price
INKT•H.C. Wainwright assumed coverage of Mink Therapeutics with a buy rating and a $38 target price.
Related News
Citigroup raises Duolingo target price to $152 from $140
DUOL•
Insulet Q3 revenue beats estimates on strong Omnipod sales
PODD•
Kraft Heinz agrees to sell North America coffee business to One Rock Capital Partners
KHC•
HP names Emma Walmsley as CEO
HPQ•
Marriott Vacations beats Q3 adjusted EPS estimates, lifts FY guidance
VAC•